Search

Your search keyword '"Kanzaki, Hiroaki"' showing total 243 results
Start Over Author "Kanzaki, Hiroaki"
243 results on '"Kanzaki, Hiroaki"'

1. Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)

Author

Kobayashi, Kazufumi, Ogasawara, Sadahisa, Itobayashi, Ei, Okubo, Tomomi, Itokawa, Norio, Nakamura, Kazuyoshi, Moriguchi, Michihisa, Watanabe, Shunji, Ikeda, Masafumi, Kuroda, Hidekatsu, Kawaoka, Tomokazu, Hiraoka, Atsushi, Yasui, Yutaka, Kuzuya, Teiji, Sato, Rui, Kanzaki, Hiroaki, Koroki, Keisuke, Inoue, Masanori, Nakamura, Masato, Kiyono, Soichiro, Kanogawa, Naoya, Kondo, Takayuki, Nakamoto, Shingo, Ozawa, Yoshihito, Tsuchiya, Kaoru, Atsukawa, Masanori, Aikata, Hiroshi, Aramaki, Takeshi, Oka, Shiro, Morimoto, Naoki, Kurosaki, Masayuki, Itoh, Yoshito, Izumi, Namiki, and Kato, Naoya

Published
2024
Full Text
View/download PDF

2. Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma

Author

Fujiwara, Kisako, Kondo, Takayuki, Fujimoto, Kentaro, Yumita, Sae, Ogawa, Keita, Ishino, Takamasa, Nakagawa, Miyuki, Iwanaga, Terunao, Tsuchiya, Satoshi, Koroki, Keisuke, Kanzaki, Hiroaki, Inoue, Masanori, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Ogasawara, Sadahisa, Nakamoto, Shingo, Chiba, Tetsuhiro, Koizumi, Jun, Kato, Jun, and Kato, Naoya

Published
2024
Full Text
View/download PDF

3. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis

Author

Fujiwara, Naoto, Lopez, Camden, Marsh, Tracey L., Raman, Indu, Marquez, Cesia A., Paul, Subhojit, Mishra, Sumit K., Kubota, Naoto, Katz, Courtney, Kanzaki, Hiroaki, Gonzalez, Michael, Quirk, Lisa, Deodhar, Sneha, Selvakumar, Pratibha, Raj, Prithvi, Parikh, Neehar D., Roberts, Lewis R., Schwartz, Myron E., Nguyen, Mindie H., Befeler, Alex S., Page-Lester, Stephanie, Srivastava, Sudhir, Feng, Ziding, Reddy, K. Rajender, Khaderi, Saira, Asrani, Sumeet K., Kanwal, Fasiha, El-Serag, Hashem B., Marrero, Jorge A., Singal, Amit G., and Hoshida, Yujin

Published
2025
Full Text
View/download PDF

5. Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis

Author

Kanzaki, Hiroaki, Ogasawara, Sadahisa, Okubo, Tomomi, Itokawa, Norio, Yoshino, Ryohei, Fujimoto, Kentaro, Kogure, Tadayoshi, Yumita, Sae, Ishino, Takamasa, Ogawa, Keita, Iwanaga, Terunao, Nakagawa, Miyuki, Fujiwara, Kisako, Kojima, Ryuta, Koroki, Keisuke, Inoue, Masanori, Kobayashi, Kazufumi, Kanogawa, Naoya, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Itobayashi, Ei, Atsukawa, Masanori, Kato, Jun, and Kato, Naoya

Published
2023
Full Text
View/download PDF

6. Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in patients with advanced hepatocellular carcinoma with macrovascular invasion: DEPARTURE trial.

Author

Koroki, Keisuke, Ogasawara, Sadahisa, Makishima, Hirokazu, Wakatsuki, Masaru, Takahashi, Asahi, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Inoue, Masanori, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Kondo, Takayuki, Nakamoto, Shingo, Shiko, Yuki, Ozawa, Yoshihito, Inaba, Yosuke, Kurokawa, Tomoya, Hanaoka, Hideki, Yamada, Shigeru, and Kato, Naoya

Published
2024
Full Text
View/download PDF

7. Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury

Author

Kondo, Takayuki, Fujimoto, Kentaro, Fujiwara, Kisako, Yumita, Sae, Ishino, Takamasa, Ogawa, Keita, Nakagawa, Miyuki, Iwanaga, Terunao, Koroki, Keisuke, Kanzaki, Hiroaki, Inoue, Masanori, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Ogasawara, Sadahisa, Nakamoto, Shingo, Chiba, Tetsuhiro, Kato, Jun, Fujiwara, Keiichi, and Kato, Naoya

Published
2023
Full Text
View/download PDF

8. Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients

Author

Kondo, Takayuki, Fujiwara, Kisako, Nakagawa, Miyuki, Fujimoto, Kentaro, Yumita, Sae, Ishino, Takamasa, Ogawa, Keita, Iwanaga, Terunao, Koroki, Keisuke, Kanzaki, Hiroaki, Inoue, Masanori, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Ogasawara, Sadahisa, Nakamoto, Shingo, Chiba, Tetsuhiro, Kato, Jun, and Kato, Naoya

Published
2023
Full Text
View/download PDF

9. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

Author

Kanogawa, Naoya, Ogasawara, Sadahisa, Maruta, Susumu, Iino, Yotaro, Obu, Masamichi, Ishino, Takamasa, Ogawa, Keita, Yumita, Sae, Iwanaga, Terunao, Unozawa, Hidemi, Nakagawa, Miyuki, Fujiwara, Kisako, Sakuma, Takafumi, Fujita, Naoto, Kojima, Ryuta, Kanzaki, Hiroaki, Koroki, Keisuke, Kobayashi, Kazufumi, Inoue, Masanori, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Saito, Tomoko, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Itobayashi, Ei, Koma, Yoshihiro, Azemoto, Ryosaku, Kato, Jun, and Kato, Naoya

Published
2023
Full Text
View/download PDF

10. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Author

Yumita, Sae, Ogasawara, Sadahisa, Nakagawa, Miyuki, Maruta, Susumu, Okubo, Tomomi, Itokawa, Norio, Iino, Yotaro, Obu, Masamichi, Haga, Yuki, Seki, Atsuyoshi, Kogure, Tadayoshi, Ishino, Takamasa, Ogawa, Keita, Fujiwara, Kisako, Iwanaga, Terunao, Fujita, Naoto, Sakuma, Takafumi, Kojima, Ryuta, Kanzaki, Hiroaki, Koroki, Keisuke, Inoue, Masanori, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Saito, Tomoko, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Itobayashi, Ei, Atsukawa, Masanori, Koma, Yoshihiro, Azemoto, Ryosaku, Ito, Kenji, Mizumoto, Hideaki, Kato, Jun, and Kato, Naoya

Published
2023
Full Text
View/download PDF

11. Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma

Author

Qiang, Na, Ao, Junjie, Nakamura, Masato, Chiba, Tetsuhiro, Kusakabe, Yuko, Kaneko, Tatsuya, Kurosugi, Akane, Kogure, Tadayoshi, Ma, Yaojia, Zhang, Jiaqi, Ogawa, Keita, Kan, Motoyasu, Iwanaga, Terunao, Sakuma, Takafumi, Kanayama, Kengo, Kanzaki, Hiroaki, Kojima, Ryuta, Nakagawa, Ryo, Kondo, Takayuki, Nakamoto, Shingo, Muroyama, Ryosuke, Kato, Jun, Mimura, Naoya, Ma, Anqi, Jin, Jian, and Kato, Naoya

Published
2023
Full Text
View/download PDF

12. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis

Author

Sakuma, Takafumi, Nakamura, Masato, Chiba, Tetsuhiro, Iwanaga, Terunao, Kan, Motoyasu, Kojima, Ryuta, Ao, Junjie, Ma, Yaojia, Unozawa, Hidemi, Fujita, Naoto, Kanayama, Kengo, Kanzaki, Hiroaki, Koroki, Keisuke, Kobayashi, Kazufumi, Nakagawa, Ryo, Kanogawa, Naoya, Kiyono, Soichiro, Kondo, Takayuki, Saito, Tomoko, Ogasawara, Sadahisa, Nakamoto, Shingo, Muroyama, Ryosuke, Kato, Jun, Kishimoto, Takashi, and Kato, Naoya

Published
2022
Full Text
View/download PDF

13. Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis

Author

Ozeki, Yusuke, Kanogawa, Naoya, Ogasawara, Sadahisa, Ogawa, Keita, Ishino, Takamasa, Nakagawa, Miyuki, Fujiwara, Kisako, Unozawa, Hidemi, Iwanaga, Terunao, Sakuma, Takafumi, Fujita, Naoto, Kojima, Ryuta, Kanzaki, Hiroaki, Koroki, Keisuke, Kobayashi, Kazufumi, Nakamura, Masato, Kiyono, Soichiro, Kondo, Takayuki, Saito, Tomoko, Nakagawa, Ryo, Suzuki, Eiichiro, Ooka, Yoshihiko, Nakamoto, Shingo, Muroyama, Ryosuke, Tawada, Akinobu, Chiba, Tetsuhiro, Arai, Makoto, Kato, Jun, Ikeda, Jun-ichiro, Takiguchi, Yuichi, and Kato, Naoya

Published
2022
Full Text
View/download PDF

14. The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma

Author

Kondo, Takayuki, Fujiwara, Kisako, Nakagawa, Miyuki, Unozawa, Hidemi, Iwanaga, Terunao, Sakuma, Takafumi, Fujita, Naoto, Koroki, Keisuke, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Saito, Tomoko, Ogasawara, Sadahisa, Suzuki, Eiichiro, Ooka, Yoshihiko, Nakamoto, Shingo, Chiba, Tetsuhiro, Arai, Makoto, Kato, Jun, and Kato, Naoya

Published
2022
Full Text
View/download PDF

15. SAT-335 Pathological dynamics and clinical implications of hepatitis in cancer patients undergoing immune checkpoint inhibitor

Author

Izai, Ryo, primary, Ogasawara, Sadahisa, additional, Akatsuka, Teppei, additional, Miwa, Chihiro, additional, Yonemoto, Takuya, additional, Yumita, Sae, additional, Nakagawa, Miyuki, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Inoue, Masanori, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Nakamoto, Shingo, additional, Komuta, Mina, additional, and Kato, Naoya, additional

Published
2024
Full Text
View/download PDF

16. Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy

Author

Inoue, Masanori, primary, Ogasawara, Sadahisa, additional, Kobayashi, Kazufumi, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Obu, Masamichi, additional, Fujimoto, Kentaro, additional, Unozawa, Hidemi, additional, Yumita, Sae, additional, Fujiwara, Kisako, additional, Nakagawa, Miyuki, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Nakamoto, Shingo, additional, Nagashima, Kengo, additional, Itobayashi, Ei, additional, Atsukawa, Masanori, additional, Koma, Yoshihiro, additional, Azemoto, Ryosaku, additional, and Kato, Naoya, additional

Published
2024
Full Text
View/download PDF

18. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

Author

Kusakabe, Yuko, Chiba, Tetsuhiro, Oshima, Motohiko, Koide, Shuhei, Rizq, Ola, Aoyama, Kazumasa, Ao, Junjie, Kaneko, Tatsuya, Kanzaki, Hiroaki, Kanayama, Kengo, Maeda, Takahiro, Saito, Tomoko, Nakagawa, Ryo, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Ogasawara, Sadahisa, Suzuki, Eiichiro, Nakamoto, Shingo, Yasui, Shin, Mikata, Rintaro, Muroyama, Ryosuke, Kanda, Tatsuo, Maruyama, Hitoshi, Kato, Jun, Mimura, Naoya, Ma, Anqi, Jin, Jian, Zen, Yoh, Otsuka, Masayuki, Kaneda, Atsushi, Iwama, Atsushi, and Kato, Naoya

Published
2021
Full Text
View/download PDF

19. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma

Author

Kanzaki, Hiroaki, Chiba, Tetsuhiro, Ao, Junjie, Koroki, Keisuke, Kanayama, Kengo, Maruta, Susumu, Maeda, Takahiro, Kusakabe, Yuko, Kobayashi, Kazufumi, Kanogawa, Naoya, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Saito, Tomoko, Nakagawa, Ryo, Ogasawara, Sadahisa, Suzuki, Eiichiro, Ooka, Yoshihiko, Muroyama, Ryosuke, Nakamoto, Shingo, Yasui, Shin, Tawada, Akinobu, Arai, Makoto, Kanda, Tatsuo, Maruyama, Hitoshi, Mimura, Naoya, Kato, Jun, Zen, Yoh, Ohtsuka, Masayuki, Iwama, Atsushi, and Kato, Naoya

Published
2021
Full Text
View/download PDF

20. Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.

Author

Ogasawara, Sadahisa, primary, Koroki, Keisuke, additional, Makishima, Hirokazu, additional, Wakatsuki, Masaru, additional, Takahashi, Asahi, additional, Kanzaki, Hiroaki, additional, Kobayashi, Kazufumi, additional, Inoue, Masanori, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Nakamoto, Shingo, additional, Shiko, Yuki, additional, Ozawa, Yoshihito, additional, Inaba, Yosuke, additional, Kurokawa, Tomoya, additional, Hanaoka, Hideki, additional, Yamada, Shigeru, additional, and Kato, Naoya, additional

Published
2024
Full Text
View/download PDF

21. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan

Author

Ogasawara, Sadahisa, Ooka, Yoshihiko, Itokawa, Norio, Inoue, Masanori, Okabe, Shinichiro, Seki, Atsuyoshi, Haga, Yuki, Obu, Masamichi, Atsukawa, Masanori, Itobayashi, Ei, Mizumoto, Hideaki, Sugiura, Nobuyuki, Azemoto, Ryosaku, Kanayama, Kengo, Kanzaki, Hiroaki, Maruta, Susumu, Maeda, Takahiro, Kusakabe, Yuko, Yokoyama, Masayuki, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Saito, Tomoko, Suzuki, Eiichiro, Nakamoto, Shingo, Yasui, Shin, Tawada, Akinobu, Chiba, Tetsuhiro, Arai, Makoto, Kanda, Tatsuo, Maruyama, Hitoshi, and Kato, Naoya

Published
2020
Full Text
View/download PDF

22. A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study

Author

Kobayashi, Kazufumi, primary, Ogasawara, Sadahisa, additional, Maruta, Susumu, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Haga, Yuki, additional, Seko, Yuya, additional, Moriguchi, Michihisa, additional, Watanabe, Shunji, additional, Shiko, Yuki, additional, Takatsuka, Hirokazu, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Inoue, Masanori, additional, Nakamura, Masato, additional, Kiyono, Soichiro, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Suzuki, Eiichiro, additional, Ooka, Yoshihiko, additional, Nakamoto, Shingo, additional, Inaba, Yosuke, additional, Ikeda, Masafumi, additional, Okabe, Shinichiro, additional, Morimoto, Naoki, additional, Itoh, Yoshito, additional, Nakamura, Kazuyoshi, additional, Ito, Kenji, additional, Azemoto, Ryosaku, additional, Atsukawa, Masanori, additional, Itobayashi, Ei, additional, and Kato, Naoya, additional

Published
2023
Full Text
View/download PDF

23. Situation of hepatitis virus tests and measures to link test-positive individuals to specialists: a survey of institutions in Chiba, Japan, specializing in liver diseases

Author

Nakamura, Masato, primary, Kiyono, Soichiro, additional, Fujimoto, Kentaro, additional, Kogure, Tadayoshi, additional, Yumita, Sae, additional, Ogawa, Keita, additional, Iwanaga, Terunao, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Inoue, Masanori, additional, Kobayashi, Kazufumi, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Ogasawara, Sadahisa, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2023
Full Text
View/download PDF

26. Exploration of new positions for cabozantinib for advanced hepatocellular carcinoma in the latest real-world practice

Author

Kanzaki, Hiroaki, primary, Ogasawara, Sadahisa, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Yoshino, Ryohei, additional, Fujimoto, Kentaro, additional, Kogure, Tadayoshi, additional, Yumita, Sae, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Iwanaga, Terunao, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Kojima, Ryuta, additional, Koroki, Keisuke, additional, Inoue, Masanori, additional, Kobayashi, Kazufumi, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Itobayashi, Ei, additional, Atsukawa, Masanori, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2023
Full Text
View/download PDF

27. Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors

Author

OGAWA, KEITA, primary, CHIBA, TETSUHIRO, additional, NAKAMURA, MASATO, additional, ARAI, JUN, additional, ZHANG, JIAQI, additional, MA, YAOJIA, additional, QIANG, NA, additional, AO, JUNJIE, additional, YUMITA, SAE, additional, ISHINO, TAKAMASA, additional, KAN, MOTOYASU, additional, IWANAGA, TERUNAO, additional, NAKAGAWA, MIYUKI, additional, FUJIWARA, KISAKO, additional, SAKUMA, TAKAFUMI, additional, KANZAKI, HIROAKI, additional, KOROKI, KEISUKE, additional, KUSAKABE, YUKO, additional, KOBAYASHI, KAZUFUMI, additional, KANOGAWA, NAOYA, additional, KIYONO, SOICHIRO, additional, KONDO, TAKAYUKI, additional, NAKAGAWA, RYO, additional, OGASAWARA, SADAHISA, additional, MUROYAMA, RYOSUKE, additional, NAKAMOTO, SHINGO, additional, KANDA, TATSUO, additional, MARUYAMA, HITOSHI, additional, KATO, JUN, additional, MATSUMOTO, SHOJI, additional, ARAI, TAKAYOSHI, additional, MOTOHASHI, SHINICHIRO, additional, and KATO, NAOYA, additional

Published
2023
Full Text
View/download PDF

28. A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.

Author

Kobayashi, Kazufumi, primary, Ogasawara, Sadahisa, additional, Maruta, Susumu, additional, Okubo, Tomomi, additional, Moriguchi, Michihisa, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kanogawa, Naoya, additional, Shiko, Yuki, additional, Inaba, Yosuke, additional, Nakamura, Kazuyoshi, additional, Azemoto, Ryosaku, additional, Ito, Kenji, additional, Okabe, Shinichiro, additional, Atsukawa, Masanori, additional, Itobayashi, Ei, additional, Ikeda, Masafumi, additional, Morimoto, Naoki, additional, Itoh, Yoshito, additional, and Kato, Naoya, additional

Published
2023
Full Text
View/download PDF

29. Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells

Author

Iwanaga, Terunao, primary, Chiba, Tetsuhiro, additional, Nakamura, Masato, additional, Kaneko, Tatsuya, additional, Ao, Junjie, additional, Qiang, Na, additional, Ma, Yaojia, additional, Zhang, Jiaqi, additional, Kogure, Tadayoshi, additional, Yumita, Sae, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Kan, Motoyasu, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Fujita, Naoto, additional, Sakuma, Takafumi, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kusakabe, Yuko, additional, Inoue, Masanori, additional, Kobayashi, Kazufumi, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Ogasawara, Sadahisa, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Kato, Jun, additional, Kanda, Tatsuo, additional, Maruyama, Hitoshi, additional, Mimura, Naoya, additional, Honda, Takuya, additional, Murayama, Toshihiko, additional, Nakamura, Hiroyuki, additional, and Kato, Naoya, additional

Published
2023
Full Text
View/download PDF

30. Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

Author

Yoshida, Ryoi, Koroki, Keisuke, Makishima, Hirokazu, Ogasawara, Sadahisa, Ishino, Takamasa, Ogawa, Keita, Nakagawa, Miyuki, Fujiwara, Kisako, Hidemi Unozawa, Iwanaga, Terunao, Fujita, Naoto, Sakuma, Takafumi, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kanogawa, Naoya, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Saito, Tomoko, Nakagawa, Ryo, Suzuk, Eiichiro, Ooka, Yoshihiko, Nakamoto, Shingo, Tawada, Akinobu, Chiba, Tetsuhiro, Arai, Makoto, Kaneko, Takashi, Wakatsuki, Masaru, Kato, Jun, Tsuji, Hiroshi, Kato, Naoya, Hirokazu, Makishima, Keita, Ogawa, Naoto, Fujita, Naoya, Kanogawa, Tomoko, Saitou, Takashi, Kaneko, Masaru, Wakatsuki, and Hiroshi, Tsuji

Abstract

Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC is systemic therapy, various treatment approaches, including resection, transarterial chemoembolization, and radiation, have been empirically suggested to improve prognosis by eliminating or controlling MVI. Herein, we report our experience of a case with advanced HCC where MVI was controlled by carbon-ion radiotherapy (CIRT) while on systemic therapy, resulting in a prolonged survival. A female patient with HCC in her early 60s had multiple intrahepatic lesions (maximum 60 mm in diameter) with PVTT. The PVTT of this patient had reached the main trunk of the portal vein despite the use of lenvatinib. The other intrahepatic lesions of the patient, except PVTT, had been controlled by lenvatinib. Therefore, hoping to control PVTT, we attempted CIRT. The patient resumed lenvatinib therapy after the irradiation. During lenvatinib re-treatment, no evident progression of PVTT was observed in the patient.

Published
2021

31. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real‐world practice

Author

Nakagawa, Miyuki, primary, Inoue, Masanori, additional, Ogasawara, Sadahisa, additional, Maruta, Susumu, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Iino, Yotaro, additional, Obu, Masamichi, additional, Haga, Yuki, additional, Seki, Atsuyoshi, additional, Kikuchi, Yasuharu, additional, Kogure, Tadayoshi, additional, Yumita, Sae, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Fujiwara, Kisako, additional, Iwanaga, Terunao, additional, Fujita, Naoto, additional, Sakuma, Takafumi, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Taida, Takashi, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Itobayashi, Ei, additional, Atsukawa, Masanori, additional, Koma, Yoshihiro, additional, Azemoto, Ryosaku, additional, Ito, Kenji, additional, Mizumoto, Hideaki, additional, Shinozaki, Masami, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

32. Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus

Author

Ma, Yaojia, primary, Nakamoto, Shingo, additional, Ao, Junjie, additional, Qiang, Na, additional, Kogure, Tadayoshi, additional, Ogawa, Keita, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Iwanaga, Terunao, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kobayashi, Kazufumi, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Ogasawara, Sadahisa, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

33. Analysis of hyperprogressive disease due to atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma

Author

Yumita, Sae, primary, Ogasawara, Sadahisa, additional, Nakagawa, Miyuki, additional, Maruta, Susumu, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Iino, Yotaro, additional, Obu, Masamichi, additional, Haga, Yuki, additional, Seki, Atsuyoshi, additional, Kogure, Tadayoshi, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Fujiwara, Kisako, additional, Iwanaga, Terunao, additional, Fujita, Naoto, additional, Sakuma, Takafumi, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Inoue, Masanori, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Itobayashi, Ei, additional, Atsukawa, Masanori, additional, Koma, Yoshihiro, additional, Azemoto, Ryosaku, additional, Ito, Kenji, additional, Mizumoto, Hideaki, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

34. Carbon‐ion radiotherapy versus radiofrequency ablation as initial treatment for early‐stage hepatocellular carcinoma

Author

Fujita, Naoto, primary, Kanogawa, Naoya, additional, Makishima, Hirokazu, additional, Ogasawara, Sadahisa, additional, Maruta, Susumu, additional, Iino, Yotaro, additional, Shiko, Yuki, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kondo, Takayuki, additional, Nakamoto, Shingo, additional, Chiba, Tetsuhiro, additional, Wakatsuki, Masaru, additional, Itobayashi, Ei, additional, Obu, Masamichi, additional, Koma, Yoshihiro, additional, Azemoto, Ryosaku, additional, Kawasaki, Yohei, additional, Kato, Jun, additional, Tsuji, Hiroshi, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

35. A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment

Author

Kato Naoya, Saito Tomoko, Kanogawa Naoya, Kato Jun, Ooka Yoshihiko, Nakamoto Shingo, Suzuki Eiichiro, Kusakabe Yuko, Maruta Susumu, Kondo Takayuki, Maruyama Hitoshi, Kobayashi Kazufumi, Yoshino Ichiro, Kanda Tatsuro, Chiba Tetsuhiro, Nakamura Masato, Tawada Akinobu, Kiyono Soichiro, Ogasawara Sadahisa, Kanzaki Hiroaki, Kanayama Kengo, Kooroki Keisuke, Sakuma Takafumi, and Kishimoto Takashi

Subjects
medicine.medical_specialty, Thesaurus (information retrieval), Lung, Hepatology, business.industry, Thoracic spine, medicine.medical_treatment, Ablation, medicine.disease, Metastasis, medicine.anatomical_structure, Hepatocellular carcinoma, medicine, Radiology, business
Published
2021
Full Text
View/download PDF

36. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

Author

Kanogawa, Naoya, primary, Ogasawara, Sadahisa, additional, Maruta, Susumu, additional, Iino, Yotaro, additional, Obu, Masamichi, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Yumita, Sae, additional, Iwanaga, Terunao, additional, Unozawa, Hidemi, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kobayashi, Kazufumi, additional, Inoue, Masanori, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kondo, Takayuki, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Itobayashi, Ei, additional, Koma, Yoshihiro, additional, Azemoto, Ryosaku, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

37. The RNA-Binding Protein ELAVL1 Regulates Hepatitis B Virus Replication and Growth of Hepatocellular Carcinoma Cells

Author

Kanzaki, Hiroaki, primary, Chiba, Tetsuhiro, additional, Kaneko, Tatsuya, additional, Ao, Junjie, additional, Kan, Motoyasu, additional, Muroyama, Ryosuke, additional, Nakamoto, Shingo, additional, Kanda, Tatsuo, additional, Maruyama, Hitoshi, additional, Kato, Jun, additional, Zen, Yoh, additional, Kotani, Ai, additional, Sekiba, Kazuma, additional, Otsuka, Motoyuki, additional, Ohtsuka, Masayuki, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

38. Risk prediction of hepatic encephalopathy after molecular targeted therapy for hepatocellular carcinoma in patients with cirrhosis

Author

Fujiwara, Kisako, primary, Kondo, Takayuki, additional, Yumita, Sae, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Nakagawa, Miyuki, additional, Unozawa, Hidemi, additional, Iwanaga, Terunao, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Ogasawara, Sadahisa, additional, Nakamoto, Shingo, additional, Chiba, Tetsuhiro, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

39. MO5-1 Regorafenib in advanced HCC patients who were not included in the RESORCE trial: first interim analysis

Author

Koroki, Keisuke, primary, Ogasawara, Sadahisa, additional, Terunao, Iwanaga, additional, Unozawa, Hidemi, additional, Fujiwara, Kisako, additional, Nakagawa, Miyuki, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kanzaki, Hiroaki, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

40. Clinical features of exacerbation of portal vein thrombosis after discontinuation of anticoagulants

Author

Kondo, Takayuki, primary, Fujiwara, Kisako, additional, Yumita, Sae, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Nakagawa, Miyuki, additional, Unozawa, Hidemi, additional, Iwanaga, Terunao, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Koroki, Keisuke, additional, Kanzaki, Hiroaki, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Ogasawara, Sadahisa, additional, Nakamoto, Shingo, additional, Chiba, Tetsuhiro, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

41. Analysis of hyperprogressive disease due to atezolizumab combined with bevacizumab treatment in patients with advanced hepatocellular carcinoma

Author

Yumita, Sae, primary, Ogasawara, Sadahisa, additional, Nakagawa, Miyuki, additional, Maruta, Susumu, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Iino, Yotaro, additional, Oobu, Masamichi, additional, Haga, Yuki, additional, Seki, Atsuyoshi, additional, Kogure, Tadayoshi, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Fujiwara, Kisako, additional, Iwanaga, Terunao, additional, Fujita, Naoto, additional, Sakuma, Takafumi, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Inoue, Masanori, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Itobayashi, Ei, additional, Atsukawa, Masanori, additional, Koma, Yoshihiro, additional, Azemoto, Ryosaku, additional, Ito, Kenji, additional, Mizumoto, Hideaki, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

42. Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial

Author

Ogasawara, Sadahisa, Koroki, Keisuke, Hirokazu, Makishima, Masaru, Wakatsuki, Sakuma, Takafumi, Naoto, Fujita, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kiyono, Souichiro, Masato, Nakamura, Naoya, Kanogawa, Tomoko, Saitou, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Hideki, Hanaoka, Hiroshi, Tsuji, Kato, Naoya, Ogasawara, Sadahisa, Koroki, Keisuke, Hirokazu, Makishima, Masaru, Wakatsuki, Sakuma, Takafumi, Naoto, Fujita, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kiyono, Souichiro, Masato, Nakamura, Naoya, Kanogawa, Tomoko, Saitou, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Hideki, Hanaoka, Hiroshi, Tsuji, and Kato, Naoya

Abstract

Background: Advanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has the worst prognosis among all HCC cases, due to its uniqueness of disease condition. Development of revolutionary therapeutic approaches to improve prognosis in these patients is an essential medical issue. A phase I/II trial demonstrated that treatment with durvalumab, an anti-programmed death-ligand 1 antibody, alone or in combination with tremelimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody, exhibited potential efficacy in patients with advanced HCC. Conversely, particle radiotherapy, including carbon-ion radiotherapy, has been shown to achieve unique dose distribution by delivering high-dose radiation to the target tumor while reducing the radiation dose to normal tissues due to its physical characteristics. Studies demonstrated that particle radiotherapy could achieve good local control in patients with HCC, including those with MVI. Additionally, particle radiotherapy as well as photon irradiation not only mediate localized tumor killing but also modify the tumor microenvironment, thereby potentiating the efficacy of immune checkpoint inhibitors. The DEPARTURE trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus particle radiotherapy is a safe and synergistically effective treatment in patients with advanced HCC and MVI. Methods: This is a phase Ib, multi-center, open-label, single-arm, investigator-initiated clinical trial to assess the safety of durvalumab monotherapy in combination with particle radiotherapy (Cohort A) and that of durvalumab plus tremelimumab in combination with particle radiotherapy (Cohort B) in advanced HCC patients with MVI who are ineligible for standard systemic therapy and Child–Pugh A liver disease. Cohort A will receive 1500 mg durvalumab every four weeks in principle. Cohort B will receive 1500 mg durvalumab every four weeks in principle and 300 mg tremelimumab only on day 1 of t

Published
2022

43. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial

Author

Ogasawara, Sadahisa, primary, Koroki, Keisuke, additional, Makishima, Hirokazu, additional, Wakatsuki, Masaru, additional, Takahashi, Asahi, additional, Yumita, Sae, additional, Nakagawa, Miyuki, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Fujiwara, Kisako, additional, Iwanaga, Terunao, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Ozawa, Yoshihito, additional, Kawasaki, Yohei, additional, Kurokawa, Tomoya, additional, Hanaoka, Hideki, additional, Tsuji, Hiroshi, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

44. 1052 PAAM FOR HEPATOCELLULAR CARCINOMA RISK STRATIFICATION IN PATIENTS WITH CIRRHOSIS: MULTICENTER PHASE 3 BIOMARKER VALIDATION STUDIES IN THE U.S.

Author

Fujiwara, Naoto, Lopez, Camden, Marsh, Tracey L., Raman, Indu, Marquez, Cesia A., Paul, Subhojit, Mishra, Sumit K., Kubota, Naoto, Katz, Courtney, Kanzaki, Hiroaki, Gonzales, Michael, Quirk, Lisa, Deodhar, Sneha, Selvakumar, Pratibha, Raj, Prithvi, Parikh, Neehar D., Roberts, Lewis R., Schwartz, Myron, Nguyen, Mindie H., Befeler, Alex, Page-Lester, Stephanie, Rinaudo, Jo Ann, Feng, Ziding, Reddy, Rajender, Khaderi, Saira, Asrani, Sumeet K., Kanwal, Fasiha, El-Serag, Hashem B., Marrero, Jorge A., Singal, Amit G., and Hoshida, Yujin

Published
2024
Full Text
View/download PDF

45. Transition of the tumor microenvironment with clonal evolution of hepatocellular carcinoma.

Author

Kanzaki, Hiroaki, primary, Ogasawara, Sadahisa, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kojima, Ryuta, additional, Koroki, Keisuke, additional, Kobayashi, Kazufumi, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Kondo, Takayuki, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Ikeda, Junichiro, additional, Ohtsuka, Masayuki, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

46. Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.

Author

Ogasawara, Sadahisa, primary, Koroki, Keisuke, additional, Makishima, Hirokazu, additional, Wakatsuki, Masaru, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kanzaki, Hiroaki, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Hanaoka, Hideki, additional, Tsuji, Hiroshi, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

47. Analysis of the tumor microenvironment in ineffective patients of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

Author

Kobayashi, Kazufumi, primary, Ogasawara, Sadahisa, additional, Ishino, Takamasa, additional, Unozawa, Hidemi, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Nakamura, Masato, additional, Kiyono, Soichiro, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

48. Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma

Author

Kondo, Takayuki, primary, Koroki, Keisuke, additional, Kanzaki, Hiroaki, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Ogasawara, Sadahisa, additional, Ooka, Yoshihiko, additional, Nakamoto, Shingo, additional, Chiba, Tetsuhiro, additional, Arai, Makoto, additional, Kato, Jun, additional, Kuboki, Satoshi, additional, Ohtsuka, Masayuki, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

49. Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience

Author

Ogawa, Keita, primary, Kanzaki, Hiroaki, additional, Chiba, Tetsuhiro, additional, Ao, Junjie, additional, Qiang, Na, additional, Ma, Yaojia, additional, Zhang, Jiaqi, additional, Yumita, Sae, additional, Ishino, Takamasa, additional, Unozawa, Hidemi, additional, Kan, Motoyasu, additional, Iwanaga, Terunao, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Fujita, Naoto, additional, Sakuma, Takafumi, additional, Koroki, Keisuke, additional, Kusakabe, Yuko, additional, Kobayashi, Kazufumi, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kondo, Takayuki, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Ogasawara, Sadahisa, additional, Suzuki, Eiichiro, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Kanda, Tatsuo, additional, Maruyama, Hitoshi, additional, Mimura, Naoya, additional, Kato, Jun, additional, Motohashi, Shinichiro, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

50. Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma

Author

Kobayashi, Kazufumi, primary, Ogasawara, Sadahisa, additional, Takahashi, Aya, additional, Seko, Yuya, additional, Unozawa, Hidemi, additional, Sato, Rui, additional, Watanabe, Shunji, additional, Moriguchi, Michihisa, additional, Morimoto, Naoki, additional, Tsuchiya, Satoshi, additional, Iwai, Kenji, additional, Inoue, Masanori, additional, Ogawa, Keita, additional, Ishino, Takamasa, additional, Iwanaga, Terunao, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Kondo, Takayuki, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Suzuki, Eiichiro, additional, Ooka, Yoshihiko, additional, Nakamoto, Shingo, additional, Tawada, Akinobu, additional, Chiba, Tetsuhiro, additional, Arai, Makoto, additional, Kanda, Tatsuo, additional, Maruyama, Hitoshi, additional, Nagashima, Kengo, additional, Kato, Jun, additional, Isoda, Norio, additional, Aramaki, Takeshi, additional, Itoh, Yoshito, additional, and Kato, Naoya, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results